Forecast report on Global Ovarian Cancer market

Published on July 7, 2014 at 2:32 AM · No Comments

Research and Markets ( has announced the addition of the "Global Ovarian Cancer Market 2014-2018" report to their offering.

Ovarian cancer is a condition where a malignancy forms in the ovarian tissue and is caused by uncontrollable cell growth. It is one of the major gynaecological cancers worldwide and a leading cause of death. Ovarian cancer is difficult to diagnose in the initial stages because the symptoms are similar to that of gastric disorders like bloating, abdominal discomfort, difficulty in eating in the early stage and nausea, vomiting, constipation and diarrhoea in the later stages.

It is often diagnosed in advanced stages when the metastasis has set in because the diagnostic techniques are not well-developed. Ovarian cancer can be treated by using chemotherapy, targeted therapy, and surgery. Although the market has a limited number of drugs for the treatment of ovarian cancer currently, a strong product pipeline is in development for the forecast period.

The analysts forecast the Global Ovarian Cancer market will grow at a CAGR of 13.85 percent over the period 2013-2018.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Rate of Incidence and Prevalence

08. Market Segmentation by Type of Therapy

09. Pipeline Portfolio

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

19. Key Vendor Analysis

20. Other Reports in this Series

Companies Mentioned:

  • Aetera Zenteris Inc.
  • Amgen Inc.
  • Aprea AB
  • Astra Zeneca plc
  • Bionumerik Pharmaceuticals Inc.
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffman-La Roche Ltd
  • Genentech Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals Inc.
  • MEI Pharmaceuticals Inc.
  • Nektar Therapeutics
  • NeoPharm Inc.
  • Novogen Inc.
  • Oasmia Pharmaceuticals AB
  • Synta Pharmaceuticals Corp.

Research and Markets

Posted in: Women's Health News

Tags: , , , , , , , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients